Changes in UK hospital mortality in the first wave of COVID-19: the ISARIC WHO Clinical Characterisation Protocol prospective multicentre observational cohort study

Annemarie B Docherty, Rachel Mulholland, Nazir Lone, Christopher P. Cheyne, Daniela De Angelis, Karla Díaz-Ordaz, Cara Donoghue, Thomas M Drake, Jake Dunning, Sebastian Funk, Marta García‐Fiñana, Michelle Girvan, Hayley Hardwick, Ewen M. Harrison, Antonia Ho, David M. Hughes, Ruth H. Keogh, Peter Kirwan, Gary Leeming, Jonathan S. Nguyen‐Van‐Tam, Riinu Pius, Clark D Russell, Rebecca G. Spencer, Brian D. M. Tom, Lance Turtle, Peter Openshaw, J. Kenneth Baillie, Malcolm G. Semple, for Isaric4c investigatorsmedRxiv 2020 · DOI

Introduction

In the early months of 2020, the UK healthcare system faced an unprecedented challenge as COVID-19 admissions surged. Initially, mortality rates were devastatingly high, but clinicians observed a noticeable decline in deaths as the first wave progressed. This study, conducted by the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), seeks to quantify the drivers behind this improvement. By disentangling the effects of patient characteristics from changes in clinical management, the research identifies what saved lives and which patient groups remained at the highest risk.

Methods and Data

The researchers utilized the ISARIC WHO Clinical Characterisation Protocol UK (CCP-UK), one of the world’s largest prospective COVID-19 datasets. The study included 63,972 adult patients admitted to 247 acute hospitals across England, Scotland, and Wales between March 9 and August 2, 2020. This cohort represented approximately 48% of all UK COVID-19 hospital admissions during that period.

To analyze the decline in mortality, the team employed a three-way decomposition mediation analysis using natural effects models. This sophisticated statistical approach allowed researchers to go beyond simple adjustments for age or health. Instead, they quantified how much of the mortality drop was "mediated" by specific changes in treatment—such as the use of steroids or different types of oxygen therapy—versus how much was due to the baseline health and severity of patients arriving at the hospital (the "case mix").

Key Findings

The Dramatic Decline in Mortality

The unadjusted hospital mortality rate plummeted during the first wave, falling from 32.3% in March/April to 16.4% in June/July 2020. This improvement was observed across all demographics, including all age groups, ethnicities, and both sexes, as well as in patients with and without pre-existing comorbidities.

Decomposing the Drivers of Survival

After adjusting for age and sex, the study found a 19% reduction in the odds of mortality for every four-week period. The mediation analysis attributed this decline to several key factors:

  • Case Mix and Severity (15.2%): Patients admitted in the earliest weeks of the pandemic were significantly more unwell at presentation, exhibiting higher inflammatory markers and lower oxygen saturation. As the wave progressed, the patient population shifted toward those with lower initial illness severity.
  • Treatment and Respiratory Support (22.2%): Changes in clinical management, specifically the introduction of steroid treatments and a shift in respiratory strategies, accounted for nearly a quarter of the survival improvement. There was a notable move away from early invasive mechanical ventilation (IMV) toward non-invasive ventilation (NIV).
  • The Unexplained Gap: Over 60% of the reduction in mortality remained unexplained by the model's specific mediators. The authors suggest this "residual" improvement likely stems from "clinical learning"—the intangible benefit of staff becoming more familiar with the disease—and community-level factors like social distancing and masking, which may have reduced the initial viral "inoculum dose" patients received.

Clinical Implications

The study highlights a significant evolution in how COVID-19 was treated on the front lines. The most dramatic survival gains were seen in the elderly; mortality for patients aged 80 and over fell from 48.0% to 25.0%.

However, the data also reveals persistent challenges. Mortality remained stubbornly high (approximately 41%) for patients requiring invasive mechanical ventilation. Furthermore, patients receiving NIV outside of a formal critical care setting also faced high risk, suggesting these groups represent distinct, high-risk phenotypes that require further targeted research.

Conclusion

The halving of hospital mortality during the UK’s first wave was a result of both a changing patient profile and rapid improvements in clinical decision-making. While the adoption of steroids and better respiratory support protocols were vital, the study underscores that severe COVID-19 remains a high-stakes condition, particularly for those requiring mechanical ventilation. These findings validate the importance of rapid clinical learning and suggest that community-wide public health measures may have contributed to less severe disease presentations at the hospital door.

Summary updated

Abstract

Abstract Background Mortality rates of UK patients hospitalised with COVID-19 appeared to fall during the first wave. We quantify potential drivers of this change and identify groups of patients who remain at high risk of dying in hospital. Methods The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) WHO Clinical Characterisation Protocol UK recruited a prospective cohort admitted to 247 acute UK hospitals with COVID-19 in the first wave (March to August 2020). Outcome was hospital mortality within 28 days of admission. We performed a three-way decomposition mediation analysis using natural effects models to explore associations between week of admission and hospital mortality adjusting for confounders (demographics, comorbidity, illness severity) and quantifying potential mediators (respiratory support and steroids). Findings Unadjusted hospital mortality fell from 32.3% (95%CI 31.8, 32.7) in March/April to 16.4% (95%CI 15.0, 17.8) in June/July 2020. Reductions were seen in all ages, ethnicities, both sexes, and in comorbid and non-comorbid patients. After adjustment, there was a 19% reduction in the odds of mortality per 4 week period (OR 0.81, 95%CI 0.79, 0.83). 15.2% of this reduction was explained by greater disease severity and comorbidity earlier in the epidemic. The use of respiratory support changed with greater use of non-invasive ventilation (NIV). 22.2% (OR 0.94, 95%CI 0.94, 0.96) of the reduction in mortality was mediated by changes in respiratory support. Interpretation The fall in hospital mortality in COVID-19 patients during the first wave in the UK was partly accounted for by changes in case mix and illness severity. A significant reduction was associated with differences in respiratory support and critical care use, which may partly reflect improved clinical decision making. The remaining improvement in mortality is not explained by these factors, and may relate to community behaviour on inoculum dose and hospital capacity strain. Funding NIHR & MRC Key points / Research in Context Evidence before this study Risk factors for mortality in patients hospitalised with COVID-19 have been established. However there is little literature regarding how mortality is changing over time, and potential explanations for why this might be. Understanding changes in mortality rates over time will help policy makers identify evolving risk, strategies to manage this and broader decisions about public health interventions. Added value of this study Mortality in hospitalised patients at the beginning of the first wave was extremely high. Patients who were admitted to hospital in March and early April were significantly more unwell at presentation than patients who were admitted in later months. Mortality fell in all ages, ethnic groups, both sexes and in patients with and without comorbidity, over and above contributions from falling illness severity. After adjustment for these variables, a fifth of the fall in mortality was explained by changes in the use of respiratory support and steroid treatment, along with associated changes in clinical decision-making relating to supportive interventions. However, mortality was persistently high in patients who required invasive mechanical ventilation, and in those patients who received non-invasive ventilation outside of critical care. Implications of all the available evidence The observed reduction in hospital mortality was greater than expected based on the changes seen in both case mix and illness severity. Some of this fall can be explained by changes in respiratory care, including clinical learning. In addition, introduction of community policies including wearing of masks, social distancing, shielding of vulnerable patients and the UK lockdown potentially resulted in people being exposed to less virus. The decrease in mortality varied depending on the level of respiratory support received. Patients receiving invasive mechanical ventilation have persistently high mortality rates, albeit with a changing case-mix, and further research should target this group. Severe COVID-19 disease has primarily affected older people in the UK. Many of these people, but not all have significant frailty. It is essential to ensure that patients and their families remain at the centre of decision-making, and we continue with an individualised approach to their treatment and care.
BibTeX
@misc{docherty2020changes,
  author = {Annemarie B Docherty and Rachel Mulholland and Nazir Lone and Christopher P. Cheyne and Daniela De Angelis and Karla Díaz-Ordaz and Cara Donoghue and Thomas M Drake and Jake Dunning and Sebastian Funk and Marta García‐Fiñana and Michelle Girvan and Hayley Hardwick and Ewen M. Harrison and Antonia Ho and David M. Hughes and Ruth H. Keogh and Peter Kirwan and Gary Leeming and Jonathan S. Nguyen‐Van‐Tam and Riinu Pius and Clark D Russell and Rebecca G. Spencer and Brian D. M. Tom and Lance Turtle and Peter Openshaw and J. Kenneth Baillie and Ewen M. Harrison and Malcolm G. Semple and for ISARIC4C investigators},
  title = {{Changes in UK hospital mortality in the first wave of COVID-19: the ISARIC WHO Clinical Characterisation Protocol prospective multicentre observational cohort study}},
  year = {2020},
  doi = {10.1101/2020.12.19.20248559},
  howpublished = {medRxiv},
}
Figure